Windward Bio Funding Round

5/4/2026

Venture Equity

$165,000,000

Series A

Proceeds will significantly extend the company's cash runway and enable multiple clinical readouts in the next 12 months.

Private & Independent

Biopharmaceutical

Aeschenplatz 6
Basel, 4052
Switzerland

Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead program is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions.